sh-Polypeptide-86 for Hair Regrowth - Quick Reference Sheet

sh-Polypeptide-86 for Hair Regrowth

Created on 09/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

sh-Polypeptide-86 is a cosmetic ingredient in scalp serums for thinning hair: a lab-made copy of follistatin, a natural protein that blocks signals holding hair follicles at rest. The idea is sound in animals, but no study has tested the ingredient on the scalp, and no regrowth effect is shown in people. Expected harm is low; the more concrete cost is time, as hair loss progresses and better-supported options exist. (Full Review)

Protocol

Standard cosmetic protocol
About 1 mL on a dry scalp
Massaged in and left on; no clinically validated dose exists and concentrations are usually undisclosed
Single vs split dosing
Once daily
Brands allow once or twice daily; no data show twice daily outperforms once; no evidence favors morning or evening
Add-on approach
Alongside proven therapy
At most an addition to minoxidil, finasteride or low-level laser therapy, never a replacement
Time to effect
Visible density
6–12 months
Typical for other topical hair treatments; no timing data exist for sh-Polypeptide-86
Shedding
3–4 months
Typical for other topical hair treatments; no timing data exist for sh-Polypeptide-86
Checkpoint
6 months
Usual point to decide on continuing, based on standardized photographs

Benefits

Contraindications
  • Pregnant or breastfeeding people, and those actively trying to conceive (all trimesters)
  • Scalp skin cancer (basal or squamous cell carcinoma) treated within the past 5 years, or basal cell nevus syndrome (an inherited gene defect)
  • Open wounds, active infection, or uncontrolled psoriasis or seborrheic dermatitis (dandruff-type scalp inflammation) at the application site
  • Known allergy to any product component
  • Undiagnosed patchy, scarring or rapid-onset hair loss (until the cause is established)
Key Interactions
  • Topical minoxidil (over-the-counter): Monitor
  • Topical retinoids (vitamin A-derived skin drugs) and exfoliating acids (tretinoin, salicylic acid, glycolic acid): Caution
  • Microneedling, dermarollers and fractional lasers: Caution
  • Anticoagulants and antiplatelet drugs (blood thinners: warfarin, apixaban, clopidogrel, aspirin): Monitor, relevant only with microneedling
  • Immunosuppressants (immune-dampening drugs: tacrolimus, cyclosporine, methotrexate): Caution
  • Injectable follistatin products (FS-344; AAV-follistatin gene therapy, using a harmless gene-carrying virus): Caution
  • Other growth-factor products (platelet-rich plasma, exosome serums containing cell-released vesicles, sh-Oligopeptide-1 serums): Caution
  • (−)-Epicatechin and cocoa flavanol supplements: Monitor, additive in principle

Risk & Side Effects

  • High:
  • Medium:
  • Low: Local scalp irritation or sensitization; delayed use of proven hair-loss treatments
  • Speculative: Slower wound healing after microneedling; uncertain skin-cancer effects; reduced skin immune sentinel cells; hormonal and reproductive effects; reactions to production residues

Monitoring

Marker Target Why
Standardized scalp photographs / target-area hair count No established target; stable or rising versus own baseline Objective efficacy endpoint
Ferritin 50–100 ng/mL Iron stores; low levels drive shedding
TSH (thyroid-stimulating hormone) 0.5–2.5 mIU/L Thyroid dysfunction causes diffuse loss
25-hydroxyvitamin D 40–60 ng/mL Deficiency is linked to hair loss
Zinc (serum) 90–120 µg/dL Deficiency can cause shedding
Hemoglobin Women 13.5–15.0 g/dL; men 14.0–16.0 g/dL Detects anemia contributing to shedding
Total testosterone (women with androgen signs) 15–40 ng/dL Excess androgen accelerates pattern loss
Scalp skin examination No new or changing lesions Screens for skin cancer and dermatitis

Cadence: Baseline before starting; photographs at 3 and 6 months, then every 6 months; blood tests at 6–12 months if a baseline value was abnormal, otherwise yearly; scalp skin examination every 12 months (every 6 months after prior skin cancer)

Qualitative Assessment

  • Daily shedding (hairs on pillow, brush or shower drain)
  • Ponytail thickness or part-line width
  • Scalp comfort: itch, redness, flaking or burning after application
  • Styling volume and how hair holds its shape
  • Lash or brow fullness where the ingredient is also applied